Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
Venous thromboembolism (VTE) is a disease that includes both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality worldwide. VTE is the third most common cardiovascular illness after acute coronary syndrome and stroke. Unfractionated heparin, low-m...
Main Authors: | Łukasz Wołowiec, Daniel Rogowicz, Krystian Kałużny, Anna Kałużna, Walery Zukow |
---|---|
Format: | Article |
Language: | English |
Published: |
Kazimierz Wielki University
2017-08-01
|
Series: | Journal of Education, Health and Sport |
Subjects: | |
Online Access: | http://www.ojs.ukw.edu.pl/index.php/johs/article/view/4833 |
Similar Items
-
Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018-09-01) -
The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review
by: Gualtiero Palareti
Published: (2014-10-01) -
Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
by: Juan J. López-Núñez, et al.
Published: (2019-01-01) -
Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index
by: Choi YJ, et al.
Published: (2021-05-01) -
Direct oral anticoagulants in cancer-associated venous thromboembolism
by: Kirill Lobastov, et al.
Published: (2020-01-01)